# Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients

> **NCT02338518** · PHASE3 · UNKNOWN · sponsor: **Jinling Hospital, China** · enrollment: 297 (actual)

## Conditions studied

- Stomach Neoplasms
- Gastric Cancer

## Interventions

- **DRUG:** oxaliplatin
- **DRUG:** etoposide
- **DRUG:** pharmorubicin
- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT02338518
- **Lead sponsor:** Jinling Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01-04
- **Primary completion:** 2019-05-21
- **Final completion:** 2023-10
- **Target enrollment:** 297 (ACTUAL)
- **Last updated:** 2023-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02338518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02338518, "Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02338518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*